Drug profile · INN
ibalizumab-uiyk
TROGARZO
ibalizumab-uiyk (TROGARZO) is a t-cell surface antigen cd4 inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — ibalizumab-uiyk
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
ibalizumab-uiyk (TROGARZO) is a t-cell surface antigen cd4 inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
T-cell surface antigen CD4 inhibitor
Primary target: T-cell surface glycoprotein CD4
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is ibalizumab-uiyk?
ibalizumab-uiyk (TROGARZO) is a t-cell surface antigen cd4 inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for ibalizumab-uiyk?
TROGARZO is a marketed brand name for ibalizumab-uiyk. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ibalizumab-uiyk?
ibalizumab-uiyk has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.